Drug Prevention of Paroxysmal Atrial Fibrillation, When and How?

  • H. J. G. M. Crijns
  • I. C. Van Gelder


Paroxysmal atrial fibrillation is self-limiting since — by definition [1] — attacks stop spontaneously, while only prolonged symptomatic episodes require drug intervention (Table 1). Despite being episodic and self-limiting, paroxysmal atrial fibrillation is a chronic disease: sooner or later after the first clinically significant attack most patients will experience a second one, even while using prophylactic antiarrhythmic drugs [2]. Therefore, drug intervention may at best reduce the number of attacks over time or postpone recurrences. Thus the primary aim of treatment is to improve quality of life rather than to simply suppress the arrhythmia. In this respect patient counseling is highly important. Patients should know that recurrences are a normal phenomenon even when using drugs, and that a breakthrough arrhythmia is not necessarily a sign of drug inefficacy. Consequently, a given drug should be replaced or non-pharmacologic treatment considered only if breakthrough arrhythmias or side effects are not tolerated.


Atrial Fibrillation Paroxysmal Atrial Fibrillation Chronic Atrial Fibrillation Drug Prevention Sick Sinus Syndrome 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sopher SM, Camm AJ (1996) Atrial fibrillation - maintenance of sinus rhythm versus rate control. Am J Cardiol 77: 24A - 38APubMedCrossRefGoogle Scholar
  2. 2.
    Suttorp MJ, Kingma JH, Koomen EM, Van’t Hof A, Tijssen JGP, Lie KI (1993) Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 71: 710–713PubMedCrossRefGoogle Scholar
  3. 3.
    Godtfredsen J (1982) Atrial fibrillation: course and prognosis. A follow-up study of 1212 cases. In: Kulbertus HE, Olsson SB, Schlepper M (eds) Atrial fibrillation. Lindgren and Söner, Mölndal, pp 134–145Google Scholar
  4. 4.
    Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE (1990) Atrial enlargement as a consequence of atrial fibrillation. Circulation 82: 792–797PubMedCrossRefGoogle Scholar
  5. 5.
    Van Gelder IC, Crijns HJGM, Blanksma PK, Landsman, MLJ, Posma JL, Van Den Berg MP, Meijler FL, Lie KI (1993) Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 72: 560–566PubMedCrossRefGoogle Scholar
  6. 6.
    Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA (1995) Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92: 1954–1968Google Scholar
  7. 7.
    Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett ELC (1994) Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol 74: 826–829PubMedCrossRefGoogle Scholar
  8. 8.
    Jenkins LS, Ellenbogen K, Kay N, Giudici M, Jensen N, Martin R, Bubien R (1995) Quality of life in patients with symptomatic atrial fibrillation. Circulation 92(I): 490 (abstr)Google Scholar
  9. 9.
    Kay GN, Bubien RS, Epstein AE, Plumb VJ (1988) Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 62: 741–744PubMedCrossRefGoogle Scholar
  10. 10.
    Brignole M, Gianfranchi L, Menozzi C, Bottoni N, Bollini R, Lolli G, Oddone D, Gaggioli G (1994) Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 74: 242–246PubMedCrossRefGoogle Scholar
  11. 11.
    Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154: 1449–1457CrossRefGoogle Scholar
  12. 12.
    Murgatroyd FD, Camm AJ (1993) Atrial arrhythmias. Lancet 341: 1317–1322PubMedCrossRefGoogle Scholar
  13. 13.
    Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82: 1106–1116Google Scholar
  14. 14.
    Carlsson J, Tebbe U, Rox J, Harmjanz D, Haerten K, Neuhaus K-L, Seidel F, Niederer W, Miketic S for the ALKK-Study group (1996) Cardioversion of atrial fibrillation in the elderly. Am J Cardiol 78: 1380–1384CrossRefGoogle Scholar
  15. 15.
    Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett ELC (1989) Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. Circulation 80: 1557–1570PubMedCrossRefGoogle Scholar
  16. 16.
    UK Propafenone PSVT Study Group (1995) A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 92: 2550–2557Google Scholar
  17. 17.
    Aliot E, Denjoy I and the Flecainide AF French Study Group (1996) Comparison of the safety and efficacy of flecainide versus propafenone in hospital-out patients with symptomatic paroxysmal atrial fibrillation/flutter. Am J Cardiol 77: 66A - 71ACrossRefGoogle Scholar
  18. 18.
    Van Wijk LM, Den Heijer P, Crijns HJGM, Van Gilst WH, Lie KI (1989) Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 13: 32–36PubMedCrossRefGoogle Scholar
  19. 19.
    Naccarelli GV, Dorian P, Hohnloser SH, Coumel P for the Flecainide Multicenter Atrial Fibrillation Group (1996) Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 77: 53A - 59ACrossRefGoogle Scholar
  20. 20.
    Reimold SC, Cantillon CO, Friedman PL, Antman EM (1993) Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 71: 558–563PubMedCrossRefGoogle Scholar
  21. 21.
    Gosselink ATM, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld ACP, Lie KI (1992) Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 267: 3289–3293PubMedCrossRefGoogle Scholar
  22. 22.
    Gilligan DM, Ellenbogen KA, Epstein AE (1996) The management of atrial fibrillation. Am J Med 101: 413–421PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1998

Authors and Affiliations

  • H. J. G. M. Crijns
    • 1
  • I. C. Van Gelder
    • 1
  1. 1.Department of Cardiology, ThoraxcenterUniversity Hospital GroningenThe Netherlands

Personalised recommendations